Kristi Rosa

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Thomas Hensing, MD, discusses the emergence of immunotherapy in the stage III non–small cell lung cancer armamentarium, and questions that must be answered to build on this initial success.

Adam M. Brufsky, MD, PhD, highlights novel treatment approaches being explored in the triple-negative breast cancer space.

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Pixatimod (PG545) in combination with the PD-1 inhibitor nivolumab (Opdivo) may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Vik Gorantla, MD, discusses ongoing developments in the adjuvant setting for patients with HER2-positive breast cancer.

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen) has been launched in the United States at a significant discount.

Mohammed Rahman, MD, discusses ongoing efforts to optimize the use of neratinib in patients with HER2-positive breast cancer.

The FDA has accepted a supplemental new drug application for review for avatrombopag (Doptelet) as a treatment for patients with chronic immune thrombocytopenia who have had an inadequate response to prior treatment.

Mary Pasquinelli, MS, APRN, discusses the pivotal role of nurses in lung cancer care.